TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
0.8901
-0.0324 (-3.51%)
At close: May 22, 2026, 4:00 PM EDT
0.9300
+0.0399 (4.48%)
After-hours: May 22, 2026, 5:31 PM EDT
TELA Bio Revenue
TELA Bio had revenue of $19.06M in the quarter ending March 31, 2026, with 2.91% growth. This brings the company's revenue in the last twelve months to $80.81M, up 13.48% year-over-year. In the year 2025, TELA Bio had annual revenue of $80.28M with 15.84% growth.
Revenue (ttm)
$80.81M
Revenue Growth
+13.48%
P/S Ratio
0.48
Revenue / Employee
$386,670
Employees
218
Market Cap
39.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 80.28M | 10.98M | 15.84% |
| Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
| Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
| Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
| Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
| Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
| Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
| Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
| Dec 31, 2017 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| Nortech Systems | 121.79M |
| Myomo | 41.21M |
| electroCore | 34.90M |
| Baird Medical Investment Holdings | 22.54M |
| Sensus Healthcare | 22.53M |
| NeuroOne Medical Technologies | 12.72M |
| Elutia | 12.46M |
TELA News
- 10 days ago - TELA Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - TELA Bio Earnings release: Q1 2026 - Filings
- 10 days ago - TELA Bio Quarterly report: Q1 2026 - Filings
- 10 days ago - TELA Bio Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 15 days ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - GlobeNewsWire
- 22 days ago - TELA Bio Proxy statement: Proxy filing - Filings
- 22 days ago - TELA Bio Proxy statement: Proxy filing - Filings